Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY22 Earnings Presentation
19 slides from Ngl Fine-chem's earnings presentation, August 2021
Slide 1: Earnings Presentation Q1FY22
Earnings Presentation Q1FY22
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by NGL Fine-Chem Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 3: Q1FY22 Financial Highlights
Q1FY22 Financial Highlights
Slide 4: Q1FY22 result highlights
Q1FY22 result highlights Consolidated Figures (Rs Cr) Q1FY22 Q1FY21 YoY Q1FY22 Revenue from operations 75.9 42.4 79.1% Revenue from operations 79.1% Cost of material consumed 32.2 16.9 Gross Profit 43.7 25.5 71.6% Rs 75.9 crores Gross Profit margin 57.6% 60.1% Employee expenses 7.5 5.4 Other expense
Slide 5: Growth across segments driven by increasing market share
Growth across segments driven by increasing market share Q1FY22 Revenue Distribution Revenue (Rs Cr) Q1FY22 Q1FY21 YoY % FY21 Human API, 4% Intermediates, 14% Veterinary API 57.9 36.1 60% 198.8 Finished Dosage Forms 4.5 2.2 104% 20.0 Finished Dosage Forms, 6% Human API 3.1 1.8 77% 19.5 Veterinary AP
Slide 6: Coupled with growth across regions
Coupled with growth across regions Q1FY22 Revenue Distribution Revenue (Rs Cr) Q1FY22 Q1FY21 YoY % FY21 ROW, 11% India, 31% Asia Pacific 19.0 16.2 17.2% 82.1 USA, 4% Europe 22.0 12.7 73.4% 80.7 India 23.2 8.4 175.9% 57.3 Asia Pacific, 25% ROW 8.5 5.1 68.0% 28.2 Europe, 29% USA 3.1 - - 6.8 6
Slide 7: Company Overview
Company Overview
Slide 8: Animal health company with strong global footprint
Animal heath company with strong global footprint Comprehensive product ▪ 22 APIs (18 veterinary API, 4 human), 4 intermediates, 10 finished dosage forms portfolio ▪ Best quality and value-driven pricing Market leadership in vet ▪ Leadership in top 3 products – 50%+ market share API ▪ Growing positi
Slide 9: Leadership in veterinary API on the back of superior quality
Leadership in veterinary API on the back of superior quality Wide Range of Product Categories Strong controls of processes with 95% in-house High quality and reliable Anthelmintics manufacturing and backward products with no market Ectoparasiticides integrated facilities leading rejection in 15 year
Slide 10: State-of-the-art manufacturing capabilities
State-of-the-art manufacturing capabilities 3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities 10,000 m2 102 m3 194 m3 Area of manufacturing Glass-lined reactors S
Slide 11: Represented by a professional team & Board
Represented by a professional team & Board Mr. Rahul Nachane Mr. Rajesh Lawande Whole-Time Director & CFO Promoters Managing Director • 30+ years of experience in the pharmaceutical industry • 20+ years of experience in the pharmaceutical industry • Is involved in the operations of the Company since
Slide 12: Advantageously placed in a growing opportunity
Advantageously placed in a growing opportunity Market Size 2020 Market Size 2027 Segment Trends Growth Drivers ▪ Pharma segment to grow ▪ Rising prevalence of at higher rate – 5.4% Animal Health zoonotic diseases, animal $192 Billion CAGR Market $139 Billion (CAGR – 4.7%) population & pet ownership
Slide 13: On strategic growth path
On strategic growth path Next leg of exponential growth Continous investments to tap 2024 Onwards opportunities New capex yet to be 2022-23 1. Greenfield capacity expansion leveraged planned at Tarapur 2019 to 2021 1. Completed Rs 20 crores expansion in Macrotech during FY22, will ▪ Capacity expansi
Slide 14: Historical Financials
Historical Financials
Slide 15: Robust financial performance
Robust financial performance Consolidated Figures Revenue (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 31% CAGR 55% CAGR 65% CAGR 258 79.7 57 153 152 116 32.1 20 21.3 19.4 13 8 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 31% 22% 60% 59% 60% 58%
Slide 16: Improving efficiencies
Improving efficiencies Consolidated Figures ROCE (%) Debt/ Equity (x) Fixed Asset Turnover (x) 0.37 53% 3.4 0.29 0.29 2.5 2.3 2.0 27% 22% 0.11 12% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 ROCE = EBIT / Avg Capital Employed (Shareholder’s Fund + Total Debt) Debt/Equity = Total Debt
Slide 17: Consolidated profit & loss statement
Consolidated profit & loss statement (Rs Cr) FY21 FY20 FY19 Revenue from operations 258.0 151.7 153.2 Cost of material consumed 102.4 64.4 62.6 Gross Profit 155.6 87.3 90.6 Gross Profit margin 60.3% 57.5% 59% Employee expenses 28.1 24.0 21.2 Other expenses 47.8 43.9 37.3 EBITDA 79.7 19.4 32.1 EBITDA
Slide 18: Consolidated balance sheet highlights
Consolidated balance sheet highlights Abridged Balance Sheet (Rs Cr) Mar-21 Mar-20 Shareholders' Funds 154 99 ▪ Net cash flow from operations of Rs Total Borrowings 16 28 27 crores was utilized in repaying Trade Payables 30 21 debt of Rs 12 crores during the year and for capex of Rs 17 crores Other
Slide 19: Thank You
Thank You NGL Fine-Chem Ltd Pareto Capital (Investor Relations) Pallavi Pednekar Pooja Dokania (Company Secretary) pooja.dokania@paretocapital.in cs@nglfinechem.com Rishav Das rishav.das@paretocapital.in 19